Citius Pharmaceuticals Clinical Trial Data
Citius Pharmaceuticals' subsidiary, Citius Oncology, presented health-related quality of life (HRQoL) data from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. The data showed that patients who responded to the treatment reported sustained improvements in skin-related quality of life measures and significant reductions in pruritus (itching).
- Counterparty
- European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG)